세계의 악성 중피종 시장 보고서(2025년)

Malignant Mesothelioma Global Market Report 2025

US $ 4,490 ￦ 6,151,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,891,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,632,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 악성 중피종 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.7%로 34억 1,000만 달러로 성장할 것으로 보입니다. 예측기간 동안의 성장은 면역요법 치료의 채용 확대, 맞춤형 의료의 중시, 저침습 수술 수술의 사용 증가, 헬스케어 지출 증가, 임상 검사수 증가에 기인하는 것으로 예측됩니다. 이 기간에 예상되는 주요 동향으로는 면역요법의 진보, 맞춤형 의료, 조기 발견에 대한 노력, 저침습 수술, 신규제의 승인 등이 있습니다.

임상 연구 개발(R&D)에 대한 노력의 중점화는 앞으로 수년간 악성 중피종 시장의 확대에 크게 기여할 것으로 예측됩니다. 임상 연구 개발에는 신약과 치료법, 의료기기 개발을 목적으로 한 과학적 연구 및 검사 실시가 포함됩니다. 이러한 노력은 관리된 임상 검사를 통해 신제품의 안전성, 효능 및 잠재적인 부작용을 평가합니다. 만성 질환과 복잡한 병태 증가로 혁신적인 치료에 대한 수요가 높아지고 있는 것이 이러한 연구개발에 대한 대처를 뒷받침하고 있습니다. 이러한 노력은 진단, 치료, 악성 중피종의 표적 요법을 진보시키고 조기 발견을 개선하고 생존율을 높이고 보다 효과적이고 침습이 적은 치료법을 만들어내는 새로운 접근법을 육성하는데 매우 중요합니다. 예를 들어 Anadolu Agency의 2025년 1월 보고서에 따르면 임상 검사는 미국 제약 연구 예산의 거의 40%를 차지하며 연간 약 70억 달러에 달할 전망입니다. 그 결과 연구개발 투자 확대가 악성 중피종 시장 성장을 가속화하고 있습니다.

악성 중피종 시장의 기업은 종양 성장을 억제하고 치료의 정확성을 높이기 위해 단일 클론 항체와 같은 최첨단 치료법의 개발에 주력하고 있습니다. 단일클론항체는 암세포 상에 존재하는 항원을 포함한 특정 항원을 검출하고, 표적으로 하는 면역계의 능력을 모방한 실험실제의 단백질입니다. 예를 들어 2023년 11월 일본 제약회사인 Ono Pharmaceutical Co. Ltd.은 인간형 항인간 PD-1 단일클론항체인 Opdivo(니볼루맙)에 대해 악성 중피종(악성 흉막 중피종 제외)에 대한 효능 및 효과의 추가 승인을 2023년 11월에 취득했습니다. 이 승인을 통해 Opdivo는 지금까지 표준 치료가 확립되지 않은 질병에 대한 새로운 치료 옵션으로 도입되었습니다. Opdivo가 이 적응증으로 희귀의약품으로 지정되었다는 것은 긴급한 의료 요구에 부응할 가능성을 강조하는 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 악성 중피종 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 악성 중피종 시장 : 성장률 분석
• 세계의 악성 중피종 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 악성 중피종 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 악성 중피종 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 악성 중피종 시장 치료 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 화학요법
• 방사선치료
• 수술
• 면역요법
• 표적요법
• 세계의 악성 중피종 시장 : 투여 경로별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 경구
• 정맥내
• 주사제
• 국소
• 세계의 악성 중피종 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원 약국
• 소매 약국
• 온라인 약국
• 전문 약국
• 세계의 악성 중피종 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원
• 종양학 클리닉
• 재활센터
• 실험실
• 세계의 악성 중피종 시장 : 화학요법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 알킬화제
• 대사 길항제
• 병용 요법
• 세계의 악성 중피종 시장 : 방사선 치료별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 외부 방사선 치료(EBRT)
• 강도조절 방사선 치료(IMRT)
• 정위 방사선 치료(SBRT)
• 양자선 치료
• 세계의 악성 중피종 시장 : 수술별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 흉막절제술 또는 흉막박리술(P/D)
• 흉막외폐절제술(EPP)
• 세포 체중 감량 수술
• 완화 수술
• 세계의 악성 중피종 시장 : 면역요법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 면역관문억제제
• 단일클론항체
• 종양 백신
• 입양세포요법
• 세계의 악성 중피종 시장 : 표적 요법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 티로신 키나아제 억제제(TKI)
• 혈관신생 억제제
• 메소테린 표적약
• 유전자 치료에 의한 접근

제7장 지역별/국가별 분석

• 세계의 악성 중피종 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 악성 중피종 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 악성 중피종 시장 : 경쟁 구도
• 악성 중피종 시장 : 기업 프로파일
  • AstraZeneca
  • NYU Langone Health
  • Mayo Foundation for Medical Education and Research
  • The University of Chicago Medical Center
  • Ono Pharmaceutical Co., Ltd.

제31장 기타 주요 기업 및 혁신 기업

• Dana-Farber Cancer Institute
• UVA Health
• PharmaMar
• Healthcare Global Enterprises Ltd.
• Fujirebio Europe
• Cancer Healer Center
• Rosetta Genomics
• Mesothelioma UK
• The Mesothelioma Center
• Oncoplus
• Mesothelioma Research Foundation of America
• Pleural Mesothelioma Center

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

• 악성 중피종 시장(2029년) : 새로운 기회를 제공하는 국가
• 악성 중피종 시장(2029년) : 새로운 기회를 제공하는 부문
• 악성 중피종 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

JHS

영문 목차

영문목차

Malignant mesothelioma is a rare and aggressive cancer that mainly affects the mesothelium, a thin tissue layer surrounding most of the internal organs. This cancer typically arises in the lung lining (pleura), but it can also develop in the abdomen (peritoneum), heart (pericardium), or testicles. The primary risk factor for malignant mesothelioma is asbestos exposure, a mineral once extensively used in construction and manufacturing.

Treatment options for malignant mesothelioma include chemotherapy, radiation therapy, surgery, immunotherapy, and targeted therapy. Chemotherapy utilizes drugs to destroy cancer cells, slow down tumor growth, and alleviate symptoms. It is commonly administered when the cancer has spread beyond the point where surgery alone would be effective. These drugs can be given through various methods, including oral, intravenous, injectable, and topical. Distribution channels for these treatments include hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, which are used by hospitals, oncology clinics, rehabilitation centers, and research laboratories.

The malignant mesothelioma market research report is one of a series of new reports from The Business Research Company that provides malignant mesothelioma market statistics, including malignant mesothelioma industry global market size, regional shares, competitors with a malignant mesothelioma market share, detailed malignant mesothelioma market segments, market trends and opportunities, and any further data you may need to thrive in the malignant mesothelioma industry. This malignant mesothelioma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The malignant mesothelioma market size has grown strongly in recent years. It will grow from $2.46 billion in 2024 to $2.63 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth observed in the historical period can be credited to increased investments in oncology research, a rise in asbestos-related litigation cases, higher hospital investments, the aging population, and the expansion of AI-driven drug discovery platforms.

The malignant mesothelioma market size is expected to see strong growth in the next few years. It will grow to $3.41 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth during the forecast period can be attributed to the growing adoption of immunotherapy treatments, a stronger emphasis on personalized medicine, increased use of minimally invasive surgical techniques, higher healthcare spending, and a greater number of clinical trials. Key trends expected during this period include advancements in immunotherapy, personalized medicine, early detection efforts, minimally invasive surgery, and the approval of new regulations.

The growing focus on clinical research and development (R&D) efforts is expected to significantly contribute to the expansion of the malignant mesothelioma market in the coming years. Clinical R&D involves conducting scientific studies and trials aimed at developing new drugs, treatments, and medical devices. These efforts assess the safety, efficacy, and potential side effects of new products through controlled clinical trials. The rising demand for innovative treatments, driven by the increasing prevalence of chronic diseases and complex conditions, is propelling these R&D initiatives. Such efforts are crucial in advancing diagnostics, treatments, and targeted therapies for malignant mesothelioma, fostering new approaches to improve early detection, enhance survival rates, and create more effective, less invasive treatment options. For instance, according to a January 2025 report by Anadolu Agency, clinical trials account for nearly 40% of the U.S. pharmaceutical research budget, amounting to about $7 billion annually. As a result, the growing investment in R&D is accelerating the growth of the malignant mesothelioma market.

Companies in the malignant mesothelioma market are concentrating on developing cutting-edge treatments, such as monoclonal antibodies, to inhibit tumor growth and enhance treatment precision. Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to detect and target specific antigens, including those found on cancer cells. For example, in November 2023, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received supplemental approval in Japan for the expanded use of Opdivo (nivolumab), a human anti-human PD-1 monoclonal antibody, for treating malignant mesothelioma (excluding malignant pleural mesothelioma). This approval introduced Opdivo as a new treatment option for a condition with no previously established standard treatments. The designation of Opdivo as an orphan drug for this indication highlights its potential to meet an urgent medical need.

In February 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Gracell Biotechnologies for $1.2 billion. This acquisition includes all of Gracell's fully diluted share capital, including the shares represented by American depositary shares. Gracell Biotechnologies, a China-based company, specializes in developing innovative cell therapies for cancer and autoimmune diseases, including malignant mesothelioma.

Major players in the malignant mesothelioma market are AstraZeneca, NYU Langone Health, Mayo Foundation for Medical Education and Research, The University of Chicago Medical Center, Ono Pharmaceutical Co., Ltd., Dana-Farber Cancer Institute, UVA Health, PharmaMar, Healthcare Global Enterprises Ltd., Fujirebio Europe, Cancer Healer Center, Rosetta Genomics, Mesothelioma UK, The Mesothelioma Center, Oncoplus, Mesothelioma Research Foundation of America, Pleural Mesothelioma Center.

North America was the largest region in the malignant mesothelioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in malignant mesothelioma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the malignant mesothelioma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The malignant mesothelioma market consists of revenues earned by entities by providing services such as genetic testing and biomarker analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant mesothelioma market includes sales of radiation therapy equipment, biopsy kits, diagnostic imaging systems, genetic testing kits, and home healthcare equipment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Malignant Mesothelioma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on malignant mesothelioma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for malignant mesothelioma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The malignant mesothelioma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Chemotherapy; Radiation Therapy; Surgery; Immunotherapy; Targeted Therapy
• 2) By Route Of Administration: Oral; Intravenous; Injectable; Topical
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies
• 4) By End-User: Hospitals; Oncology Clinics; Rehabilitation Centres; Research Laboratories
• Subsegments:
• 1) By Chemotherapy: Alkylating Agents; Antimetabolites; Combination Therapy
• 2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Intensity-Modulated Radiation Therapy (IMRT); Stereotactic Body Radiation Therapy (SBRT); Proton Therapy
• 3) By Surgery: Pleurectomy Or Decortication (P/D); Extrapleural Pneumonectomy (EPP); Cytoreductive Surgery; Palliative Surgery
• 4) By Immunotherapy: Immune Checkpoint Inhibitors; Monoclonal Antibodies; Tumor Vaccines; Adoptive Cell Therapy
• 5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Angiogenesis Inhibitors; Mesothelin-Targeted Agents; Gene Therapy-Based Approaches
• Companies Mentioned: AstraZeneca; NYU Langone Health; Mayo Foundation for Medical Education and Research; The University of Chicago Medical Center; Ono Pharmaceutical Co., Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Malignant Mesothelioma Market Characteristics

3. Malignant Mesothelioma Market Trends And Strategies

4. Malignant Mesothelioma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Malignant Mesothelioma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Malignant Mesothelioma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Malignant Mesothelioma Market Growth Rate Analysis
• 5.4. Global Malignant Mesothelioma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Malignant Mesothelioma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Malignant Mesothelioma Total Addressable Market (TAM)

6. Malignant Mesothelioma Market Segmentation

• 6.1. Global Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Radiation Therapy
• Surgery
• Immunotherapy
• Targeted Therapy
• 6.2. Global Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Injectable
• Topical
• 6.3. Global Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies
• 6.4. Global Malignant Mesothelioma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Oncology Clinics
• Rehabilitation Centres
• Research Laboratories
• 6.5. Global Malignant Mesothelioma Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alkylating Agents
• Antimetabolites
• Combination Therapy
• 6.6. Global Malignant Mesothelioma Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy (EBRT)
• Intensity-Modulated Radiation Therapy (IMRT)
• Stereotactic Body Radiation Therapy (SBRT)
• Proton Therapy
• 6.7. Global Malignant Mesothelioma Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pleurectomy Or Decortication (P/D)
• Extrapleural Pneumonectomy (EPP)
• Cytoreductive Surgery
• Palliative Surgery
• 6.8. Global Malignant Mesothelioma Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Checkpoint Inhibitors
• Monoclonal Antibodies
• Tumor Vaccines
• Adoptive Cell Therapy
• 6.9. Global Malignant Mesothelioma Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors (TKIs)
• Angiogenesis Inhibitors
• Mesothelin-Targeted Agents
• Gene Therapy-Based Approaches

7. Malignant Mesothelioma Market Regional And Country Analysis

• 7.1. Global Malignant Mesothelioma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Malignant Mesothelioma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Malignant Mesothelioma Market

• 8.1. Asia-Pacific Malignant Mesothelioma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Malignant Mesothelioma Market

• 9.1. China Malignant Mesothelioma Market Overview
• 9.2. China Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Malignant Mesothelioma Market

• 10.1. India Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Malignant Mesothelioma Market

• 11.1. Japan Malignant Mesothelioma Market Overview
• 11.2. Japan Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Malignant Mesothelioma Market

• 12.1. Australia Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Malignant Mesothelioma Market

• 13.1. Indonesia Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Malignant Mesothelioma Market

• 14.1. South Korea Malignant Mesothelioma Market Overview
• 14.2. South Korea Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Malignant Mesothelioma Market

• 15.1. Western Europe Malignant Mesothelioma Market Overview
• 15.2. Western Europe Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Malignant Mesothelioma Market

• 16.1. UK Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Malignant Mesothelioma Market

• 17.1. Germany Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Malignant Mesothelioma Market

• 18.1. France Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Malignant Mesothelioma Market

• 19.1. Italy Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Malignant Mesothelioma Market

• 20.1. Spain Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Malignant Mesothelioma Market

• 21.1. Eastern Europe Malignant Mesothelioma Market Overview
• 21.2. Eastern Europe Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Malignant Mesothelioma Market

• 22.1. Russia Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Malignant Mesothelioma Market

• 23.1. North America Malignant Mesothelioma Market Overview
• 23.2. North America Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Malignant Mesothelioma Market

• 24.1. USA Malignant Mesothelioma Market Overview
• 24.2. USA Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Malignant Mesothelioma Market

• 25.1. Canada Malignant Mesothelioma Market Overview
• 25.2. Canada Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Malignant Mesothelioma Market

• 26.1. South America Malignant Mesothelioma Market Overview
• 26.2. South America Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Malignant Mesothelioma Market

• 27.1. Brazil Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Malignant Mesothelioma Market

• 28.1. Middle East Malignant Mesothelioma Market Overview
• 28.2. Middle East Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Malignant Mesothelioma Market

• 29.1. Africa Malignant Mesothelioma Market Overview
• 29.2. Africa Malignant Mesothelioma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Malignant Mesothelioma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Malignant Mesothelioma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Malignant Mesothelioma Market Competitive Landscape And Company Profiles

• 30.1. Malignant Mesothelioma Market Competitive Landscape
• 30.2. Malignant Mesothelioma Market Company Profiles
  • 30.2.1. AstraZeneca Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. NYU Langone Health Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Mayo Foundation for Medical Education and Research Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. The University of Chicago Medical Center Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Ono Pharmaceutical Co., Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Malignant Mesothelioma Market Other Major And Innovative Companies

• 31.1. Dana-Farber Cancer Institute
• 31.2. UVA Health
• 31.3. PharmaMar
• 31.4. Healthcare Global Enterprises Ltd.
• 31.5. Fujirebio Europe
• 31.6. Cancer Healer Center
• 31.7. Rosetta Genomics
• 31.8. Mesothelioma UK
• 31.9. The Mesothelioma Center
• 31.10. Oncoplus
• 31.11. Mesothelioma Research Foundation of America
• 31.12. Pleural Mesothelioma Center

32. Global Malignant Mesothelioma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Malignant Mesothelioma Market

34. Recent Developments In The Malignant Mesothelioma Market

35. Malignant Mesothelioma Market High Potential Countries, Segments and Strategies

• 35.1 Malignant Mesothelioma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Malignant Mesothelioma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Malignant Mesothelioma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료